Capmatinib (Tabrecta) for Metastatic Non-small cell lung cancer (NSCLC)

Capmatinib (Tabrecta) for Metastatic Non-small cell lung cancer (NSCLC)

What is Capmatinib? Efficacy and Safety of a Targeted Cancer Drug Used in a MET Gene AlterationПодробнее

What is Capmatinib? Efficacy and Safety of a Targeted Cancer Drug Used in a MET Gene Alteration

Will Tabrecta Cure Lung CancerПодробнее

Will Tabrecta Cure Lung Cancer

Tabrecta (capmatinib)-metastatic non-small cell lung cancer (NSCLC)Подробнее

Tabrecta (capmatinib)-metastatic non-small cell lung cancer (NSCLC)

FDA Priority Review of Capmatinib for METex14-Mutated NSCLCПодробнее

FDA Priority Review of Capmatinib for METex14-Mutated NSCLC

Oncology MoA AnimationПодробнее

Oncology MoA Animation

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLCПодробнее

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC